Surgery Partners: A 'Buy' After Idaho Falls Asset Divestment

Summary I initiate coverage of Surgery Partners with a Buy, citing positives relating to the Idaho Falls divestiture. SGRY's asset sale reduces leverage, improves cash flow, and shifts payor mix away from Medicaid. That also simplifies its business and boosts its valuation appeal as a short-stay surgical pure-play. I see significant upside from the $60B inpatient-to-outpatient migration, supported by robust practitioner recruitment and disciplined acquisition strategy. Looking for more investing ideas like this one? Get them exclusively at Asia Value & Moat Stocks. Learn More » laddawan punna/iStock via Getty Images I'm initiating coverage of Surgery Partners, Inc. ( SGRY ) with a 'Buy.' Following the recent asset disposal, SGRY's financial and operational profile is anticipated to be bolstered across various dimensions like balance-sheet leverage, cash flow conversion, and business This article was written by The Value Pendulum 13.6K Followers Follow The Value Pendulum is an Asian equity market specialist with over a decade of experience on both the buy and sell sides.He is the author of the investing group Asia Value & Moat Stocks, providing ideas for value investors seeking investment opportunities listed in Asia, with a particular focus on the Hong Kong market. He hunts for deep value balance sheet bargains and wide moat stocks and provides a range of watch lists with monthly updates within his investing group. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.